Skip to content
Toggle main navigation
TEPHIConnect logo
TEPHIConnect logo
  • Home
  • About
    • About TEPHINET
    • About TEPHIConnect
    • Terms of Use and Privacy
  • How to Join
  • Why Join?
  • News
  • Events
  • Groups
  • Journals
    • BMC Medicine
    • BMC Medical Research Methodology
    • Clinical Epidemiology and Global Health
    • Emerging Microbes & Infections
    • Frontiers in Epidemiology
    • Global Health Journal
    • International Journal of Epidemiology
    • Online Library Journal
    • PLoS One
    • Science Direct Journal (Global Health)
    • Science Direct Journal (Clinical Epidemiology and Global Health)
    Log in
    Request to join

    News

    All
    abstract
    access to care
    acute febrile Illness
    adolescents
    adults
    afenet
    afghanistan
    africa
    african american
    alaskapox
    alumni spotlight
    amazon
    americas
    analysis
    antarctica
    See all

    Results (8)

    Overcoming barriers to cervical screening attendance among underrepresented populations in Europe

    Overcoming barriers to cervical screening attendance among underrepresented populations in Europe

    The World Health Organisation (WHO) European region released a roadmap in response to the call to action to eliminate cervical cancer by the end of the century with the core principle of “leaving no one behind”. To eliminate cervical cancer (reduce incidence below 4 in 100,000) equitably, high rates of HPV vaccination, screening participation and treatment of pre-cancers and management of invasive
    May 20, 2024
    Burden of intracerebral haemorrhage in Europe: forecasting incidence and mortality between 2019 and 2050

    Burden of intracerebral haemorrhage in Europe: forecasting incidence and mortality between 2019 and 2050

    BackgroundAnticipating the burden of intracerebral haemorrhage is crucial for proactive management and building resilience against future health challenges. Prior forecasts are based on population demography and to a lesser extent epidemiological trends. This study aims to utilise selected modifiable risk factors and socio-demographic indicators to forecast the incidence and mortality of intracere
    February 14, 2024
    Urgent health update: rising measles cases in Kazakhstan

    Urgent health update: rising measles cases in Kazakhstan

    Kazakhstan is currently grappling with a significant health crisis, as measles cases have increased fivefold since the summer. According to the CDC, the country ranks third in the world in measles cases, trailing only Yemen and India. This fact is particularly striking given Kazakhstan's relatively low population of 20 million, in sharp contrast to India's 1.4 billion.Continue reading
    February 1, 2024
    Monitoring progress towards universal health coverage in Europe: a descriptive analysis of financial protection in 40 countries

    Monitoring progress towards universal health coverage in Europe: a descriptive analysis of financial protection in 40 countries

    BackgroundEnsuring that access to health care is affordable for everyone—financial protection—is central to universal health coverage (UHC). Financial protection is commonly measured using indicators of financial barriers to access (unmet need for health care) and financial hardship caused by out-of-pocket payments for health care (impoverishing and catastrophic health spending). We aim to assess
    February 1, 2024
    Heterogeneity of treatment effect of higher dose dexamethasone by geographic region (Europe vs. India) in patients with COVID-19 and severe hypoxemia – a post hoc evaluation of the COVID STEROID 2 trial

    Heterogeneity of treatment effect of higher dose dexamethasone by geographic region (Europe vs. India) in patients with COVID-19 and severe hypoxemia – a post hoc evaluation of the COVID STEROID 2 trial

    BackgroundIn the COVID-STEROID 2 trial there was suggestion of heterogeneity of treatment effects (HTE) between patients enrolled from Europe vs. India on the primary outcome. Whether there was HTE for the remaining patient-centred outcomes is unclear.MethodsIn this post hoc analysis of the COVID-STEROID 2 trial, which compared 12 mg vs. 6 mg dexamethasone in adults with COVID-19 and severe hypoxe
    January 10, 2024
    The effect of temporal data aggregation to assess the impact of changing temperatures in Europe: an epidemiological modelling study

    The effect of temporal data aggregation to assess the impact of changing temperatures in Europe: an epidemiological modelling study

    BackgroundDaily time-series regression models are commonly used to estimate the lagged nonlinear relation between temperature and mortality. A major impediment to this type of analysis is the restricted access to daily health records. The use of weekly and monthly data represents a possible solution unexplored to date.MethodsWe temporally aggregated daily temperatures and mortality records from 14
    January 2, 2024
    Rare diseases: still on the fringes of universal health coverage in Europe

    Rare diseases: still on the fringes of universal health coverage in Europe

    Despite general advancements in population health indicators and universal health coverage, people living with rare diseases and their families still experience considerable unmet needs, including prolonged diagnostic journeys, limited treatment options, and a huge psychosocial burden due to the lack of coordinated, integrated care. Attainment of universal health coverage for rare diseases is depe
    December 18, 2023
    Efficacy and safety of MP1032 plus standard-of-care compared to standard-of-care in hospitalised patients with COVID-19: a multicentre, randomised double-blind, placebo-controlled phase 2a trial

    Efficacy and safety of MP1032 plus standard-of-care compared to standard-of-care in hospitalised patients with COVID-19: a multicentre, randomised double-blind, placebo-controlled phase 2a trial

    SARS-CoV-2 infections still have a significant impact on the global population. The existing vaccinations have contributed to reducing the severe disease courses, decreasing hospitalisations, and lowering the mortality rate. However, due to the variability of COVID-19 symptoms, the emergence of new variants and the uneven global distribution of vaccines there is still a great need for new therapy
    December 11, 2023
    Contact
    TEPHINET Secretariat

    330 W Ponce de Leon Ave

    Decatur

    GA 30030

    USA

    tephinet@taskforce.org
    +1-404-371-0466
    Links
    • Training Programs in Epidemiology and Public Health Interventions Network (TEPHINET)
    • Privacy Policy
    Cookies
    Reselect cookie settings
    Community engagement platform by Hivebrite.